<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784221</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003671-17</org_study_id>
    <nct_id>NCT04784221</nct_id>
  </id_info>
  <brief_title>Reirradiation by Nanoparticles and Hypofractionated Protontherapy of Relapsed Tumors: Non-randomized Phase II Study.</brief_title>
  <acronym>NANOPRO</acronym>
  <official_title>Reirradiation by Nanoparticles and Hypofractionated Protontherapy of Relapsed Pan-tumors: Non-randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter non-randomized phase II study: proton therapy with&#xD;
      nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter non-randomized phase II study: proton therapy with&#xD;
      nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously in&#xD;
      recurrent tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local efficacy of a treatment combining the administration of nanoparticles with proton therapy</measure>
    <time_frame>2 years after the treatment</time_frame>
    <description>proportion of patients alive and without local progression two years after the start of proton therapy (local progression-free survival rate)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Recurrent Cancer</condition>
  <condition>Previous Radiation</condition>
  <arm_group>
    <arm_group_label>Radiation by protontherapy associated to nanoparticles injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation by protontherapy associated to nanoparticles injection</intervention_name>
    <description>Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.&#xD;
Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.&#xD;
The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy</description>
    <arm_group_label>Radiation by protontherapy associated to nanoparticles injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 18 or over&#xD;
&#xD;
          -  Patient with tumor of the cephalo-spino-iliosacral axis corresponding to the spectrum&#xD;
             of tumors treated in protontherapy, particularly base of the skull, pharyngeal wall,&#xD;
             parapharyngeal and retropharyngeal lymph nodes, cavum without associated lymph node,&#xD;
             pre-spinal tumor, etc. tumors are immobile as opposed to visceral thoracic, abdominal&#xD;
             and pelvic tumors which may be mobile which will be excluded because they cannot be&#xD;
             irradiated in proton therapy in the current state of the art),&#xD;
&#xD;
          -  Tumor already irradiated, within more than 6 months before inclusion&#xD;
&#xD;
          -  Patient with a relapse or a new tumor in irradiated territory&#xD;
&#xD;
          -  Tumor considered to be radioresistant (TCD50&gt; 50Gy)&#xD;
&#xD;
          -  Dosimetry (s) of previous irradiations available&#xD;
&#xD;
          -  Progressive tumor in tissue already irradiated to at least 40 Gy EQD2 (α / β = 2)&#xD;
&#xD;
          -  Indication of reirradiation by protontherapy for curative purposes. The indication for&#xD;
             reirradiation by protontherapy will be discussed depending on the size and location of&#xD;
             the tumor (particularlyfor a volume of less than or equal to 113 ml of PTV in an ENT&#xD;
             situation may be taken into account), the presence of previous toxicities. It will be&#xD;
             validated by RCP at the Center François Baclesse&#xD;
&#xD;
          -  The patient may have received previous systemic treatment&#xD;
&#xD;
          -  Evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Performance Status ≤ 2&#xD;
&#xD;
          -  Normal renal function: creatinine clearance ≥ 50 ml / min&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Patient having given written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mobile tumors&#xD;
&#xD;
          -  Lymphomas, brain tumors (gliomas), meningiomas, skin carcinomas, malignant melanomas&#xD;
             (skin or mucous membranes), tumor of the larynx, mobile lesions of the oral cavity&#xD;
&#xD;
          -  Recurrence occurring within 6 months of the end of the first irradiation&#xD;
&#xD;
          -  Patient with a contraindication to radiotherapy&#xD;
&#xD;
          -  Patient with progressive visceral or cerebral metastases&#xD;
&#xD;
          -  Life-threatening comorbidities within two years&#xD;
&#xD;
          -  Patient with a contraindication to MRI&#xD;
&#xD;
          -  Immovable metallic material in the target volume (significant imaging artefacts)&#xD;
&#xD;
          -  Impossibility of completely immobilizing the target volume (moving organ)&#xD;
&#xD;
          -  Large volume to be irradiated (PTV) for an acceptable benefit / risk balance evaluated&#xD;
             in RCP of the François Baclesse Center&#xD;
&#xD;
          -  Neoplasic skin ulceration&#xD;
&#xD;
          -  Doses previously received by OARs or radiation toxicity already present preventing&#xD;
             reirradiation including in protontherapy (clinical and dosimetric study of each case)&#xD;
&#xD;
          -  Concomitant cancer treatment such as chemotherapy, immunotherapy, targeted therapy or&#xD;
             other, underway or planned to be initiated during irradiation&#xD;
&#xD;
          -  Simultaneous participation in another therapeutic clinical trial&#xD;
&#xD;
          -  Patient deprived of liberty, under guardianship or curatorship&#xD;
&#xD;
          -  Pregnant or breastfeeding patient&#xD;
&#xD;
          -  Patient unable to undergo medical monitoring of the trial for geographic, social or&#xD;
             psychopathological reasons&#xD;
&#xD;
          -  History of other malignant disease in the past 3 years, except skin cancer other than&#xD;
             melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without&#xD;
             bone marrow involvement) must have been treated and not show signs of recurrence for&#xD;
             at least 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Delphine LEROUGE, MD</last_name>
    <phone>332455050</phone>
    <email>d.lerouge@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques BALOSSO, Prof</last_name>
    <phone>332455050</phone>
    <email>j.balosso@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>protontherapy</keyword>
  <keyword>nanoparticles</keyword>
  <keyword>AguIX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

